Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
4.320
-0.120 (-2.70%)
At close: Apr 28, 2026, 4:00 PM EDT
4.270
-0.050 (-1.16%)
After-hours: Apr 28, 2026, 4:04 PM EDT
Company Description
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases.
Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.
The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018.
The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Camp4 Therapeutics Corporation
| Country | United States |
| Founded | 2016 |
| IPO Date | Oct 11, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 48 |
| CEO | Joshua Mandel-Brehm |
Contact Details
Address: One Kendall Square, 3rd Floor Cambridge, Massachusetts 02139 United States | |
| Phone | 617 651 8867 |
| Website | camp4tx.com |
Stock Details
| Ticker Symbol | CAMP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.00 |
| CIK Code | 0001736730 |
| CUSIP Number | 13463J101 |
| ISIN Number | US13463J1016 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joshua Mandel-Brehm | Chief Executive Officer, President and Director |
| Dr. Richard A. Young Ph.D. | Founder and Independent Director |
| Kelly Gold | Chief Financial Officer |
| Dr. Yuri Maricich M.B.A., M.D. | Chief Medical Officer |
| Dr. Leonard I. Zon M.D. | Founder and Chairman of Scientific Advisory Board |
| Caleb Moore | Chief Business Operations Officer |
| Dr. Daniel Tardiff Ph.D. | Chief Scientific Officer |
| Michelle Gates | Senior Vice President and Chief People Officer |
| Alla Sigova Ph.D. | Senior Vice President of Platform |
| Dr. Satya Kuchimanchi Ph.D. | Senior Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2026 | ARS | Filing |
| Apr 23, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 24, 2026 | 8-K | Current Report |
| Mar 11, 2026 | SCHEDULE 13D/A | Filing |
| Mar 5, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 5, 2026 | 10-K | Annual Report |
| Mar 5, 2026 | 8-K | Current Report |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Feb 5, 2026 | SCHEDULE 13G/A | Filing |